The company’s board of directors has declared an interim dividend of Rs. 11.00 per share for FY26, against Rs 10.50 per share interim dividend for the previous year.
U.S. formulation sales were $477 million, up marginally by 0.6%. The company’s innovative drug business continued to grow in the US, offsetting the decline in its generic drug business. US sales accounted for approximately 27.5% of total consolidated sales. Through the first nine months, sales were $1,445 million.
Global sales of innovative medicines reached $423 million in Q3FY26. This included a milestone income of $55 million. Before the milestone, global sales of innovative medicines increased by 13.2% and accounted for 21.2% of sales. Through the first nine months, revenue was $1,067 million, up 15.7% from the same period last year.
Sales of formulations in India stood at Rs 49,98.60 crore, up 16.2%. India Formulation’s revenue accounted for 32.3% of total consolidated revenue.
Sun’s innovative R&D pipeline includes five new clinical-stage entities. It has an extensive product offering in the US market, consisting of approved ANDAs for 550 products, while filings for 116 ANDAs are awaiting US FDA approval, including 28 provisional approvals. During the quarter, 2 ANDAs were submitted and approval was received for 2 ANDAs. Sun’s portfolio includes 57 approved NDAs, while 14 NDAs are awaiting US FDA approval. End
#Sun #Pharmas #profit #rises #yearoveryear #branded #innovative #companies #drive #growth